John Dvor serves as Executive Vice President Nth America. Previously, he was Managing Director at Miraki Innovation, a $200M early-stage medtech VC fund, which founded Auris Health, acquired by Johnson & Johnson for $5.75B.  He was co-founder of Tufts Health Ventures, investment division of Tufts Health Plan, investing $250M in digital health technologies, such as Iora Health, acquired by Amazon. As an operator he has held executive roles at iRobot Corporation, ReMed Life Sciences, and 3BL Holdings, executing strategic partnerships, investments and M&A deals. He has advised several leading family office conglomerates, including Helge Capital, Agon Ventures and Aga Khan Foundation. Mr. Dvor earned his Bachelor’s Degree from Harvard University.  His career started in the US Marine Corps at The White House and was awarded Presidential Service Badge #17996.

Orly Amiran holds a master degree in Quality Assurance from the Technion and a B.Sc. in Pharmacy from the Hebrew University. She has worked in the pharmaceutical industry since 2001 and has extensive experience in Quality Assurance management in global companies which market drugs to the European market and to North America. Prior to joining Pluri Orly held the positions of Quality Assurance Manager at TEVA and Compliance Manager at Taro. She played a central role in successful regulatory agencies inspections in both positions. Ms. Orly Amiran brings with her to Pluri a vast experience and knowledge on GMP, quality regulations and the corresponding industry best practices.

Dr. Arthur Machlenkin joined Pluri in May 2022 and serves as Chief Scientific Officer. He is a biotech industry professional with nearly 20 years of academic and industrial experience at the intersection of drug discovery and development. He was most recently CEO at Pantheon Biosciences, an Israeli early-stage biotechnology company translating the bacterial immunity into antiviral platforms and therapeutics. As CEO, he led Pantheon’s vision and strategy, built an international team of top-notch researchers and academic collaborators. Prior to Pantheon, Arthur spent four years at Compugen where he was a Head of Immuno-Oncology (I-O) Research with responsibility for building the I-O infrastructure of the company and for target validation process. Before Compugen, Arthur spent 10 years in Hadassah Medical Center as Principal Investigator. He co-led (with Prof. Lotem) basic and translational research, discovery and development of innovative anticancer cell therapies including adoptive cell transfer and genetically modified tumor vaccines. Arthur has a PhD from Weizmann Institute of Science.

Efrat Kaduri,  now Chief Business Development Officer – Pharma, was appointed Vice President Business Development in February 2022, after serving as Director of Business Development and Marketing since October 2019 and, prior to that, as Director of Business, Investor and Public Relations since 2014. Before Joining Pluri, Mrs. Kaduri worked as a strategic advisor and spokesperson for several business entities including technological incubators, medical and agrotech startups. Previous positions also included Elron Electronic Industries (TASE: ELRN), the technology investment arm of IDB group. Mrs. Kaduri holds a Master of Business Administration (MBA) from the Haifa University and a BA in Psychology and Communications from the City University of New York.

Efrat Livne-Hadass, Chief Wellbeing Officer, manages the organizational Culture and Wellbeing of the company, and is responsible for organizational development, recruitment, welfare, etc. Efrat joined Pluri-Biotech in 2007 and while holding that position, she was involved in some major challenges and change processes which the company was going through. Before joining Pluri-Biotech and during the years 2001-2005, Mrs. Livne-Hadass held the position of HR Manager at EVS, located in Yokneam, Israel. Efrat is MBTI certified – The Myers-Briggs Type Indicator Instrument of CPP and the Israeli Center for MBTI.

Certified “Conscious Capitalism” and a member of the “Israeli Conscious Capitalism’s friends’ associates and ambassadors”. A member at the Israeli “Corporate Happiness Community”. A regular lecturer at the “Conscious Capitalism” Leadership course, and at the Israeli “Corporate Happiness Academy”. Mrs. Livne-Hadass holds an M.A. Executive degree in Human Resources Management from the Department of Labor Studies, Tel Aviv University and a B.Sw. Bachelor’s degree from the University of Haifa.

Nimrod Bar Zvi joined Pluri as chief commercial officer in 2022 to lead global commercialization of the company’s cell-based technology Platform. Mr. Bar Zvi brings extensive senior leadership experience in the global pharmaceutical markets and active ingredients, with over 15 years in executives roles building B2B strategies, CDMO, API & Pharma sales. Prior to joining Pluri, Nimrod was the CEO of a UK CDMO inhalation company, Pharmaserve NW and led the transformation to new green propellants in devices used to deliver respiratory drugs. Previously, Mr. Bar Zvi held various supply chain and commercial executive roles for Teva Pharmaceuticals and was responsible for developing Teva API growth strategy and entering new markets and businesses worldwide. Prior to that he served as Head of their North America, LATAM and China API commercial offices responsible for over 300m$ annual sales operations globally. Previously, he led Teva API Commercial operations in Europe and execution of strategic acquisitions for the region including establishment of new offices in Russia and prior to that he managed new established sales forces for Teva International Group in the Far-East markets with representation in over 15 Countries including first offices in China Mainland.

Dr. Michal Sheleg joined Pluri in July 2017 and currently holds the position of Vice President of Clinical Development, where she oversees clinical programs, regulatory strategy, and the data department. Prior to her current role, she served as both a Research Manager and Medical Director at Pluri, contributing to the organization’s research and medical initiatives. Dr Sheleg completed her postdoctoral research at the Department of Neurobiology and Ethology in Haifa University. She holds a PhD in Toxicology from the University of Medicine and Dentistry of New Jersey and Rutgers, the State University of New Jersey Joint Graduate Program and holds a BS with Honors in Biology and Mathematics from Saint Peter’s University in NJ.

Mr. Yaky Yanay was appointed as CEO from June 2019 after serving as President from February 2014.  Mr. Yanay served in variety of executive positions in Pluri since 2006 including Co-CEO, Chief Financial Officer, Chief Operating Officer and Executive Vice President. Mr. Yanay is the former Co-Chairman and current board member of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israel’s life science and high-tech industries. Mr. Yanay founded over the years several activities and organizations to promote and support the Israeli life science industry. Before joining Pluri, Mr. Yanay was the Chief Financial Officer of Elbit Vision Systems Ltd. a public, machine vision, high-tech company. Prior to that Mr. Yanay served as manager at Ernst & Young Israel. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting and is a Certified Public Accountant in Israel.

Liat Zalts is the Chief Financial Officer and Treasurer of Pluri where she is responsible for managing the financial & corporate strategy. Prior to her appointment as CFO, Mrs. Zalts served as Pluri’s Director of Finance. Mrs. Zalts joined Pluri from Matics Manufacturing Analytics Ltd., a SaaS, high-tech company based in Israel, where she served as CFO. Before Matics, Mrs. Zalts worked at Ernst & Young Israel (EY) and served as a manager of audit groups relating to public and private companies in the high-tech department. Mrs. Zalts holds a bachelor’s degree in economics and business management from Haifa University, a degree in accounting from Bar Ilan University and is a Certified Public Accountant in Israel.

Lior Raviv joined Pluri in 2011 and currently serves as Chief Technology Officer. Prior to that Mr. Raviv served as VP Operations & Development, Process Development Engineer, Projects Manager and Product development Team leader at Pluri. Prior to joining Pluri and during the years 2010-2011, Mr. Raviv held the position of R&D Analytical Researcher at Teva Pharmaceutical Industries. Mr. Raviv holds a M.Med.Sec in pharmacology from the Ben Gurion University and a B.S.c, in Biotechnology engineering from the Ben Gurion University.

©2023 Pluri Inc.

©2023 Pluri Inc., its logo, brand, product, and process names appearing in this issue are the trademarks of Pluri™ Inc. or its affiliated companies. All other brand, product, and process names appearing are the trademarks of their respective holders. Reference to or use of a product, or process other than those of Pluri™ Inc. does not imply recommendation, approval, affiliation, or sponsorship of that product, or process by Pluri™ Inc. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent, copyright, trademark, or other intellectual property right of Pluri™ Inc. or any third party, except as expressly granted herein.  All information herein is for general information only and is subject for change without notice.

NAME

Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.